- Home
- FMAO vs RVNC Comparison
FMAO vs RVNC Comparison
Compare FMAO & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- RVNC
- Stock Information
- Founded
- FMAO 1897
- RVNC 1999
- Country
- FMAO United States
- RVNC United States
- Employees
- FMAO N/A
- RVNC N/A
- Industry
- FMAO Savings Institutions
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- RVNC Health Care
- Exchange
- FMAO Nasdaq
- RVNC Nasdaq
- Market Cap
- FMAO 290.9M
- RVNC 546.4M
- IPO Year
- FMAO N/A
- RVNC 2014
- Fundamental
- Price
- FMAO $27.39
- RVNC $5.28
- Analyst Decision
- FMAO Hold
- RVNC Buy
- Analyst Count
- FMAO 2
- RVNC 10
- Target Price
- FMAO $26.00
- RVNC $10.86
- AVG Volume (30 Days)
- FMAO 17.0K
- RVNC 1.8M
- Earning Date
- FMAO 10-28-2024
- RVNC 11-06-2024
- Dividend Yield
- FMAO 3.16%
- RVNC N/A
- EPS Growth
- FMAO N/A
- RVNC N/A
- EPS
- FMAO 1.56
- RVNC N/A
- Revenue
- FMAO $95,411,000.00
- RVNC $251,178,000.00
- Revenue This Year
- FMAO N/A
- RVNC $20.36
- Revenue Next Year
- FMAO $7.89
- RVNC $31.66
- P/E Ratio
- FMAO $18.03
- RVNC N/A
- Revenue Growth
- FMAO N/A
- RVNC 40.23
- 52 Week Low
- FMAO $16.90
- RVNC $2.30
- 52 Week High
- FMAO $28.76
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- FMAO 52.40
- RVNC 43.99
- Support Level
- FMAO $25.93
- RVNC $5.10
- Resistance Level
- FMAO $28.76
- RVNC $5.43
- Average True Range (ATR)
- FMAO 0.64
- RVNC 0.17
- MACD
- FMAO 0.11
- RVNC 0.02
- Stochastic Oscillator
- FMAO 57.19
- RVNC 64.29
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.